Skip to main content

Table 5 Adverse effects among different single-nucleotide polymorphisms

From: Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone

 

C100T

C2851T

G4181C

C/C

C/T

T/T

Statistics

P

C/C

C/T

Statistics

P

C/C

C/G

Statistics

P

Weight change from week 0 to 4

2.3(0.0, 4.3)

2.0(− 0.8, 4.0)

1.0(− 1.0, 2.5)

3.238

0.198

− 1.0(− 3.0, 1.0)

−4.0(−7.6, − 0.3)

−3.091

0.008

−1.3(− 3.0, 0.4)

−1.5(− 3.8, 1.0)

− 0.163

0.871

Weight change from week 0 to 8

− 3.0(− 4.4, − 0.5)

0.0(−5.0, 0.6)

− 1.0(−2.6, 1.2)

3.487

0.175

− 1.0(− 4.0, 1.0)

−1.5(− 4.0, 0.0)

− 0.533

0.594

− 1.0(− 4.0, 1.3)

0.0(−5.0, 0.0)

− 0.510

0.610

BMI change from week 0 to 8

− 1.1(− 1.8, − 0.2)

0.0(−1.7, 0.2)

− 0.4(− 1.0, 0.4)

4.010

0.135

− 0.4(− 1.6, 0.3)

(−1.6, 0.0)

− 0.680

0.496

− 0.4(− 1.6, 0.4)

0.0(− 1.7, 0.0)

− 0.469

0.639

GLU change from week 0 to 4

−0.1(− 0.4, 0.5)

−0.3(− 1.1, 0.2)

−0.5(− 1.3, 0.1)

2.776

0.250

− 0.3(− 0.9, 0.2)

− 0.4(− 1.2, − 0.1)

− 0.673

0.501

−0.6(− 1.2,-0.1)

− 0.1(− 0.5, 0.4)

−2.401

0.016

GLU change from week 0 to 8

−0.4(− 0.9, − 0.3)

−0.4(− 0.8, 0.6)

−0.2(− 0.7, 0.2)

0.106

0.899

− 0.2(− 0.8, 0.3)

−0.4(− 0.8, − 0.2)

0.447

0.847

−0.4(− 0.7, 0.1)

− 0.3(− 0.9, 0.6)

0.095

0.870

TG change from week 0 to 4

0.5(− 0.1, 1.7)

0.0(− 0.3, 0.5)

0.0(− 0.3, 0.4)

4.156

0.125

0.1(− 0.2, 0.6)

− 0.2(− 0.5, 0.5)

−1.497

0.134

−0.1(− 0.4, 0.4)

0.4(0.0, 0.9)

− 3.206

0.001

TG change from week 0 to 8

0.3(−0.2, 1.3)

− 0.1(− 0.4, 0.3)

0.0(− 0.2, 0.3)

2.879

0.237

0.1(− 0.3, 0.4)

0.0(− 0.5, 0.5)

−0.030

0.976

0.1(−0.5, 0.4)

0.1(− 0.2, 0.4)

−0.824

0.410

CHO change from week 0 to 4

−0.1(− 1.0, 1.1)

− 0.4(− 0.9, 0.3)

−0.3(− 0.8, 0.0)

2.813

0.067

− 0.2(− 0.8, 0.3)

−0.4(− 1.0, 0.0)

0.411

0.105

− 0.3(− 1.0, 0.1)

− 0.2(− 0.6, 0.4)

0.097

0.053

CHO change from week 0 to 8

−0.3(− 1.2, 0.5)

− 0.5(− 1.0, 0.3)

0.0(− 0.9, 0.4)

0.448

0.641

−0.4(− 0.9, 0.4)

−0.4(− 1.5, 0.5)

6.350

0.309

− 0.6(− 1.0, 0.4)

− 0.3(− 0.7, 0.3)

− 0.901

0.346

LDL change from week 0 to 4

0.2(−0.5, 0.8)

− 0.1(− 0.4, 0.3)

−0.1(− 0.5, 0.2)

2.430

0.095

0.0(− 0.5, 0.4)

0.0(− 0.3, 0.2)

0.316

0.413

− 0.2(− 0.5, 0.2)

0.0(− 0.4, 0.4)

0.009

0.069

LDL change from week 0 to 8

0.1(− 0.7, 0.8)

−0.4(− 0.6, 0.2)

−0.1(− 0.5, 0.5)

0.947

0.393

− 0.2(− 0.6, 0.4)

−0.1(− 0.7, 0.3)

0.997

0.708

− 0.2(− 0.7, 0.3)

0.0(− 0.6, 0.4)

− 1.243

0.214

HDL change from week 0 to 4

−0.1(− 0.2, 0.1)

−0.1(− 0.2, 0.0)

−0.1(− 0.3, 0.1)

0.227

0.839

− 0.1(− 0.2, 0.1)

−0.2(− 0.3, 0.0)

−2.073

0.038

−0.1(− 0.2, 0.0)

0.0(− 0.2, 0.0)

3.847

0.939

HDL change from week 0 to 8

−0.2(− 0.3, 0.0)

−0.1(− 0.3, 0.0)

−0.1(− 0.2, 0.1)

1.129

0.569

− 0.1(− 0.2, 0.1)

−0.2(− 0.4, 0.0)

4.061

0.035

0.0(− 0.2, 0.1)

−0.1(− 0.3, 0.0)

− 1.089

0.341

PRL change from week 0 to 4

−56.6(− 117.3, − 10.5)

−42.5(− 98.8, − 16.0)

− 28.6(− 108.8, − 0.7)

0.376

0.828

39.4(5.0, 82.6)

42.5(12.1, 131.4)

−0.786

0.432

50.3(5.9, 128.3)

39.5(12.3, 100.4)

4.276

0.584

PRL change from week 0 to 8

57.4(0.0, 131.5)

46.4(25.3, 78.1)

33.4(1.8, 66.2)

0.71

0.492

33.4(1.8, 64.3)

81.7(30.7, 133.7)

−2.179

0.029

37.2(18.0, 79.0)

40.8(7.1, 82.9)

−0.399

0.690

ESRS week 4

3

6

7

0.144

0.570

15

5

−0.094

0.578

12

3

−1.771

0.085

ESRS week 8

3

7

10

0.525

0.828

15

5

−0.094

0.578

13

4

−1.740

0.094

BAS week 4

1

4

3

0.741

0.693

4

3

−1.167

0.353

5

3

−0.152

0.598

BAS week 8

1

5

3

0.596

0.653

7

2

−0.124

0.634

4

5

−0.912

0.472

  1. Data are presented as median (interquartile range). Abbreviations: BAS Barnes Akathisia Scale, BMI Body mass index, CHO Cholesterol, ESRS Extrapyramidal Symptom Rating Scale, GLU Glucose, HDL High-density lipoprotein, LDL Low-density lipoprotein, PRL Prolactin, TG Triglyceride